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Abstract We performed a meta-analysis of weight loss and
remission of type 2 diabetes mellitus (T2DM) evaluated in
randomized controlled trials (RCTs) and observational studies
of bariatric surgery vs conventional medical therapy. English
articles published through June 10, 2013 that compared bar-
iatric surgery with conventional therapy and included T2DM
endpoints with ≥12-month follow-up were systematically
reviewed. Body mass index (BMI, in kilogram per square
meter), glycated hemoglobin (HbA1C, in degree), and fasting
plasma glucose (FPG, in milligram per deciliter) were ana-
lyzed by calculating weighted mean differences (WMDs) and
pooled standardized mean differences and associated 95 %
confidence intervals (95 % CI). Aggregated T2DM remission
event data were analyzed by calculating the pooled odds ratio
(POR) and 95 % CI. Random effects assumptions were ap-
plied throughout; I2≥75.0 % was considered indicative of
significant heterogeneity. Systematic review identified 512
articles: 47 duplicates were removed, 446 failed inclusion
criteria (i.e., n<10 per arm, animal studies, reviews, case
reports, abstracts, and kin studies). Of 19 eligible articles,
two not focused on diagnosed T2DM and one with insuffi-
cient T2DM data were excluded. In the final 16 included
papers, 3,076 patients (mean BMI, 40.9; age, 47.0; 72.0 %
female) underwent bariatric surgery; 3,055 (39.4; 48.6,
69.0 %) received conventional or no weight-loss therapy. In
bariatric surgery vs conventional therapy groups, the mean
17.3±5.7 month BMI WMD was 8.3 (7.0, 9.6; p<0.001;
I2=91.8), HbA1C was 1.1 (0.6, 1.6; p<0.001; I
2=91.9), and
FPG, 24.9 (15.9, 33.9; p<0.001; I2=84.8), with significant
differences favoring surgery. The overall T2DM remission
rate for surgery vs conventional group was 63.5 vs 15.6 %
(p<0.001). The Peto summary POR was 9.8 (6.1, 15.9);
inverse variance summary POR was 15.8 (7.9, 31.4). Of the
included studies, 94.0 % demonstrated a significant statistical
advantage favoring surgery. In a meta-analysis of 16 studies
(5 RCTs) with 6,131 patients and mean 17.3-month follow-
up, bariatric surgery was significantly more effective than
conventional medical therapy in achieving weight loss,
HbA1C and FPG reduction, and diabetes remission. The odds
of bariatric surgery patients reaching T2DM remission ranged
from 9.8 to 15.8 times the odds of patients treated with
conventional therapy.
Keywords Bariatric . Metabolic . Comparative . Type 2
diabetesmellitus . T2DM . Systematic review .
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Introduction
“Diabesity,” a term coined by Dr. Ethan Sims in 1973 to
denote comorbid obesity and type 2 diabetes mellitus
(T2DM) [1], has steadily grown into a global epidemic. The
World Health Organization (WHO) estimates the number of
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overweight adults at >1.6 billion and >400 million who are
obese. By 2015, >2.3 billion adults are projected to be over-
weight with >700 million obese [2]. Globally, >312 million
people suffer from T2DM [3], a disease associated with a
markedly increased risk of heart disease and stroke, micro-
and macrovascular consequences, retinopathy, and kidney
failure [4]. While weight loss and its maintenance, by any
means, aids in improving and managing T2DM [5, 6], long-
term antidiabetic diet compliance is poor even when supported
by pharmacotherapy; 50.0 to 90.0 % of patients remain unable
to achieve adequate diabetes control [7–9].
In the long-running, prospective, controlled Swedish
Obese Subjects (SOS) study, weight loss by conventional
medical therapy was associated with T2DM remission of
approximately 21.0 % (n=248) at 2 years (compared with
72.0 % remission in postbariatric surgery patients [n=342])
and 12.0 % (n=84) at 10 years (vs 37.0 % bariatric surgery
group remission [n=118]) [10], an approximately threefold
difference in effective control of diabetes favoring bariatric
surgery. Typically, when even excellent weight loss has been
achieved by very low calorie diets (VLCDs) and intensive
lifestyle programs, neither weight loss nor diabetes resolution
has been maintained beyond 1–5 years [10–13] nor has dia-
betes resolved as rapidly as following most bariatric proce-
dures (i.e., within days to a few weeks [14]). Several series
suggest that although the weight-loss effect of bariatric sur-
gery is attenuated in lower body mass index (BMI, in kilo-
gram per square meter) patients [15, 16], surgery may achieve
a higher rate of diabetes resolution than conventional medical
therapy in patients who are only overweight (BMI≥25–29.9)
through those with class III obesity (BMI≥40.0) [17–19].
Diabetes and obesity are progressive, multifactorial diseases;
it is probable that bariatric surgery and/or one of the emerging,
less-invasive, endolumenal procedures in combination with
life-long lifestyle modification may represent an optimum
management strategy [11, 20, 21].
Procedures that most effectively reduce weight, such as
Roux-en-Y gastric bypass (RYGB) and biliopancreatic diver-
sion, realize 80.0 and 95.0 % hyperglycemia remission, respec-
tively [22], a markedly greater treatment effect than that seen in
the majority of studies of conventional dietary and pharmaco-
logic therapy; most patients fail to achieve the goal for glycemic
control of <7.0 % glycated hemoglobin (HbA1C) prescribed by
the American Diabetes Association (ADA) [23, 24]. The etiol-
ogy of diabetes remission following bariatric surgery is not
fully understood. Remission may be engaged by divergent
and/or additional mechanisms through bariatric surgery [25],
as individual procedures reorganize the gastrointestinal (GI)
tract differently, activating varied neurohormonal mechanisms
[26, 27]. Preclinical [28] and clinical evidence [19, 29, 30]
suggest that improved glycemic control is not linked exclu-
sively with baseline weight or operative weight loss and
results from complementary processes [15, 22, 31–33].
Our aim was to assess diabetes and weight outcomes in
comparative studies of bariatric surgery vs conventional med-
ical therapy. In preliminary research, we found few directly
comparative, level 1, randomized controlled trial (RCT) out-
comes (as defined by the Oxford Centre for Evidence-Based
Medicine [34]). As a result, we broadened our inclusion
criteria to incorporate directly comparative observational stud-
ies (OSs). Thus, the current review systematically identified
and screened comparative studies of bariatric surgery vs
conventional medical therapy in adults with a mean
BMI≥25 and subjected the aggregated weight and diabetes
data (BMI, HbA1C, fasting plasma glucose (FPG), and diabe-
tes remission) to meta-analysis.
Methods
Inclusion Criteria and Search Strategy
An electronic literature search and cross-referencing of articles
was performed within the following databases: National Li-
brary of Medicine PubMed®/MEDLINE®, SpringerLink®,
and SciVerse®. The search strategy followed the identification
and screening guidelines established by the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [35]. Articles were identified by Boolean
combination of keywords: “bariatric surgery,” “metabolic
surgery,” “diabetes surgery,” “gastric band,” “sleeve gastrec-
tomy,” “gastric bypass,” “duodenal switch,” “biliopancreatic
diversion,” with “medical treatment,” “medical therapy,”
“conventional treatment,” “conventional therapy,” and “diet.”
An additional search using keyword phrases, “bariatric sur-
gery, diabetes mellitus,” and “bariatric surgery, glucose OR
insulin OR HbA1C or HOMA,” was run. Limits set to govern
the searches stipulated journal articles that featured compara-
tive studies on adult human subjects written in the English
language with no beginning date through June 10, 2013.
Compiled article citations were screened by title to exclude
duplicates arising from unintentional collection of both
e-publications and their follow-on print versions. The unique
citations were evaluated by review of abstracts. Articles with
n<10 in any study arm, reviews, animal studies, case reports,
abstracts, book chapters, kin studies (i.e., reports with over-
lapping data, or outcomes reported for the same timeframe
and/or by the same author group), and Comments or Letters to
the Editor were excluded from eligibility. The remaining
articles were read in full and assessed by two researchers to
ensure that all or a subset of the overweight, mildly obese, or
morbidly obese patients in each treatment arm had been
diagnosed with T2DM (of any duration) prior to undergoing
bariatric surgery or conventional therapy. Finally, articles
evaluating fewer than one of the aforementioned T2DM end-
points were excluded from quantitative analysis.
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Defining Diabetes Remission and Data Extraction
The recommended glycemic goal for HbA1C stipulated by the
2009ADAStandards ofMedical Care in Diabetes for adults is
<7.0 % with a suggested normal range of 4.0–6.0 % [24]. A
variety of definitions of T2DM remission have been used in
bariatric surgery and conventional medical therapy studies. In
the current analysis, the percentage of patients that achieved
T2DM remission, as assessed independently in each included
study, characterized T2DM remission rate.
Variable data of interest were extracted from included
studies and entered into a dedicated database. Data collection
objectives centered on study characteristics (including bariat-
ric procedures, conventional treatments, study designs, and
analysis time points); demographic and anthropometric mea-
sures (age, gender, BMI [weight (in kilogram), divided by
height (in square meter)] [36]); markers of glycemic control
(HbA1C and FPG); and T2DM remission rate. Assessment of
study quality indicated that a range of diverse medical therapies
characterized the non-surgical control groups. In addition, cer-
tain studies combined outcome data from multiple bariatric
surgery procedures and presented results in the form of a
general surgery group vs conventional therapy; no stratification
was used. The present authors opted to extend the concept of
“grouping” to each study that met inclusion criteria; i.e., if
studies reported on more than two arms (e.g., multiple surgery
procedures and/or multiple forms of conventional therapy), data
were pooled using weighted means and standard deviations to
represent summary data for one “combined surgery group” vs
one “combined conventional therapy group” per study.
Statistical Analysis
Data manipulation and analysis were conducted using SPSS®
software, version 20.0 (IBM SPSS, Chicago, IL, USA) in con-
junction with Comprehensive Meta Analysis 2.2 (Biostat, En-
glewood, NJ, USA). Body mass index, HbA1C, and FPG were
analyzed by calculatingweightedmean differences (WMDs) and
pooled standardizedmean differences (SMDs) and associated 95%
confidence intervals (CI). Aggregated T2DM remission event data
were analyzed by calculating the pooled odds ratio (POR) and 95%
CI. Random effects assumptions were applied throughout; I2≥
75.0 % was considered indicative of significant heterogeneity.
[See Electronic Supplementary Material, Appendix 1 includ-
ing references 37–40 for detailed statistical methodology.]
Results
Study Characteristics
The results of the systematic review are presented in Fig. 1. A
total of 512 articles were identified by extensive electronic
database search. Forty-seven duplicates were removed. After
screening 465 unique citations by title and abstract, 446 failed
to meet inclusion criteria and were excluded. The remaining
17 articles were read and assessed for eligibility. Two that
provided neither primary nor secondary outcomes related to
patients with diagnosed T2DM and one that provided insuffi-
cient T2DM data to assess at the 12-month analysis time point
were excluded, leaving a final set of 16 articles [41–56] for
quantitative analysis.
Characteristics of included studies are described in Table 1.
Comparative articles were published over a slightly less than
10-year span, between December 23, 2004 and June 10, 2013,
the majority (13/16, 81.3 %) in the last 3.5 years. The respec-
tive country of origin (based on first author’s affiliation) and
article distribution was: USA, six (38.0 %); Italy, four
(25.0 %); Australia, two (12.5 %); Norway, two (12.5 %);
Sweden, one (6.0 %); and Korea, one (6.0 %). Study designs
included 5 (31.0 %) nonblinded RCTs, 11 OSs, 3 (19.0 %)
nonrandomized controlled trials (nRCTs), 5 (31.0 %) prospec-
tive comparison studies, and 3 (19.0 %) retrospective database
reviews. All studies obtained local institutional or ethics review
board protocol approval, 12 mentioned obtaining informed con-
sent, and 8 were nationally registered as clinical trials. Often,
more than one WHO weight class was studied in a report: 11
(69.0 %) included morbidly obese patients, 4 (25.0 %) obese, 5
(31.3 %) mildly obese, and 1 (6.3 %) overweight. Our analysis
focused on results collected between 12 and 24 months follow-
ing study commencement. Mean follow-up was 17.3±
5.7 months (median 15.0 months). T2DM remission was de-
fined variably across studies; however, the target criteria was
always identical for the two arms within each individual study.
Bariatric surgical procedures employed were well-
accepted, frequently performed operations [57]: Roux-en-Y
gastric bypass (11; 69.0 %), laparoscopic adjustable gastric
banding (LAGB; 5, 25.0 %), biliopancreatic diversion (BPD;
3, 18.8%), laparoscopic sleeve gastrectomy (LSG; 3, 18.8%),
vertical banded gastroplasty (VBG; 1, 6.3 %), and duodenal
switch (DS; 1, 6.3 %). Conventional therapies ranged from
intensive weight loss programs with initial VLCDs graduating
to moderate calorie intake combined with lifestyle modifica-
tion training and diabetologist-managed T2DM treatment; to
those with structured, rehabilitative inpatient programs; some
that included routine medical management of T2DM and self-
monitored weight-loss and exercise plans; to a few programs
with no educational plan or dietary supervision.
Preliminary Analysis of RCTs vs OSs
Analysis of variance using pooled summary data indicated no
statistically significant baseline differences between RCT sur-
gery, RCT conventional, OS surgery, and OS conventional
patient groups with respect to age ((mean [SE]) (45.8 [2.0],
47.1 [1.4], 46.6 [2.0], 49.7 [1.4]), respectively; F(3, 6,127)=
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0.83, p=0.50), BMI ((37.5 [1.7], 42.5 [1.2], 37.2 [1.8], 40.3
[1.2]); F(3, 6,127)=1.23, p=0.30, HbA1C (8.9 [0.6], 7.6 [0.4],
7.8 [0.6], 7.1 [0.4]); F(3, 1,517)=1.84, p=0.14), and FPG
(163.0 [8.7], 136.3 [7.9], 156.1 [11.7], 134.0 [10.43]);
F(3, 4,926)=0.52 ( p=0.67). In light of these findings, data
were integrated from RCTs and OSs to make direct compar-
isons between bariatric surgery and conventional therapy
groups at baseline.
Patient Characteristics and Baseline Clinical Profile
The total number of patients in the included studies was 6,131;
3,076underwent bariatric surgery and 3,055 underwent con-
ventional treatment. The mean age of patients included in this
meta-analytic research was 47.8 years, ranging from 35.8 to
62.0 years. Relative to the conventional treatment group
(CTG), the bariatric surgery group (BSG) was slightly youn-
ger (47.0 years [95 % CI, 45.3, 48.7] vs 48.6 years [46.6,
50.7]; pooled SMD=−0.23 [−0.28, −0.18], p<0.05; I2=
0.0 %), and was comprised of a somewhat greater percentage
of females (72.0 vs 69.0 %, p<0.01). Overall baseline com-
parability statistics for select clinical variables (i.e., BMI
[mean data available on 16 studies/100 %], HbA1C
[12/75 %], and FPG [11/69 %]) are presented in Table 2.
The summary statistics indicated that, on average and relative
to the CTG, BSG patients had a higher mean baseline BMI
(40.9 kg/m2 [38.5, 43.3] vs 39.4 kg/m2 [37.3, 41.6]; pooled
SMD=0.33 [0.16, 0.51], p<0.001; I2=84.0 %), a higher
HbA1C level (8.0 % [7.1, 9.0] vs 7.7 % [6.8, 8.5]; pooled
SMD=0.39 [0.12, 0.67], p<0.01; I2=84.0 %), and a higher
FPG level (150.3 mg/dL [135.7, 164.9] vs 143.1 mg/dL [129.8,
156.3]; pooled SMD=0.15 [0.02, 0.28], p<0.05; I2=84.0 %).
These data suggest that the BSG and the CTG were fairly well-
matched at baseline along variables relevant to the study of
T2DM remission. The mean SMD characterizing baseline dif-
ferences was 0.28 (0.15–0.39), a value considered to represent a
“small” statistical and clinical mean difference between groups
and an approximate distribution overlap of 80.0–85.0 %.
Assessment of Within-Group Change in Clinical Markers
After Treatment
Table 3 presents meta-analytic data summarizing mean base-
line (pretreatment), mean follow-up (post-treatment), and
Fig. 1 Outcomes of the
systematic review of the literature
by record identification,
screening, and analysis in the
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mean change values in BMI, HbA1C, and FPG for each of the
studies within the two treatment groups (i.e., BSG and CTG).
Pooled estimates of overall means and mean change (WMD)
are also provided. The weighted mean baseline BMI for the
BSG was 40.9 kg/m2 (95 % CI, 38.5, 43.3), with a follow-up
weighted mean BMI of 29.4 kg/m2 (27.8, 30.9). TheWMD in
BMI for BSG patients was 11.4 kg/m2 ([95 % CI, 10.0, 12.9],
statistical significance of overall effect: p<0.001, I2=95.0 %).
In contrast, the weighted mean baseline BMI for the
CTG was 39.4 kg/m2 (37.3, 41.6), with a follow-up
weighted mean BMI of 37.8 kg/m2 (35.6, 39.9). The
WMD for all patients undergoing some form of con-
ventional therapy was 1.6 kg/m2 ([0.7, 2.6], p<0.01,
I2=86.5 %).
Within-group mean changes in HbA1C and FPG tended to
follow the pattern of change observed in BMI. At baseline, the
BSG had a weighted mean HbA1C of 8.0 % (7.1, 9.0), with a
follow-up of 6.1 % (5.8, 6.4), a reduction that represented an
overall WMD of 2.0 % ([1.2, 2.8], p<0.001, I2=86.5 %) for
BSG patients. The CTG was found to have a weighted mean
baseline HbA1C of 7.7 % (6.8, 8.5), with a follow-up of 7.2 %
(6.6, 7.7). The WMD in HbA1C levels following conventional
therapy was 0.47 % ([0.1, 0.9], p<0.05; I2=90.1 %). Similar-
ly, the BSG had a baseline weighted mean FPG of 150.3 mg/
dL (135.7, 164.9), with a follow-up of 95.3 mg/dL (89.3,
101.3). The WMD was 53.3 mg/dL ([40.0, 66.7], p<0.001;
I2=96.8 %). Finally, baseline weighted mean FPG for the
CTG was 143.1 mg/dL (129.8, 156.3), with a follow-up of
123.2 mg/dL (113.3, 133.1). The WMD in FPG levels for
conventional therapy patients was 17.4 mg/dL ([8.8, 26.0],
p<0.001; I2=89.2 %). Figures 2 and 3 depict trend lines
characterizing the relative changes over time in BMI and
HbA1C levels for BSG and CTG groups stratified by study
design.
Assessment of Between-Group Differences in Clinical
Markers After Treatment
The WMD comparing BSG and CTG on follow-up BMI for
combined OS data (k=11; n=5,257) was −8.5 kg/m2 ([−10.2,
−6.9], p<0.001; I2=93.0 %); whereas, the corresponding
WMD for combined RCT data (k=5; n=440) was
−7.7 kg/m2 ([−10.1, −5.3], p<0.001; I2=87.5 %), with
a high degree of 95 % CI overlap. No significant
heterogeneity (Q p value=0.573) was found between
the OSs’ summary estimate and the RCTs’ summary
estimate with respect to the magnitude and direction of
treatment effect on BMI, with the surgery group favored
in both study designs.
The WMD comparing BSG vs CTG on follow-up
HBA1C, for combined OS data (k=8; n=1,131) was −0.89 %
([−1.3, −0.45], p<0.001; I2=91.7 %); whereas, the corre-



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































OBES SURG (2014) 24:437–455 445
−1.43 % ([−2.1, −0.81], p<0.001; I2=66.2 %), with signif-
icant 95 % CI overlap. No significant heterogeneity (Q
p value=0.16) was found between the OSs’ summary esti-
mate and the RCTs’ summary estimate with respect to the
magnitude and direction of treatment effect on HBA1C, with
the surgery group favored in both study designs.
TheWMD comparing BSG vs CTG on follow-up FPG, for
combined OS data (k=6; n=4,460) was −20.9 mg/dL ([−29.3,
−12.5]; p<0.001; I2=84.3 %); whereas, the corresponding
WMD for combined RCT studies (k=5; n=440) was
−30.1 mg/dL ([−40.8, −19.5], p<0.001; I2=80.5 %), with a



















































































































































































































































































































































































































































































































































































































































































































Fig. 2 Mean body mass index (BMI) reduction in bariatric surgery
patients and conventional therapy patients by study design (randomized
controlled trial vs observational)
Fig. 3 Mean glycated hemoglobin (HbA1C) reduction in bariatric surgery
patients and conventional therapy patients by study design (randomized
controlled trial vs observational)
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(Q p value=0.18) was found between the OSs’ summary
estimate and the RCTs’ summary estimate with respect to the
magnitude and direction of treatment effect on FPG, with the
surgery group favored in both study designs.
In summary, independent treatment effect sizes for
both OSs and RCTs were sufficiently concordant to
permit estimation of an overall effect for each analysis
presented in Fig. 4. The first three meta-analytic results
(BMI, HbA1C, and FPG) provide individual study mean
follow-up differences and SEs, as well as independent
summary estimates for OSs and RCTs, and the overall
WMD for combined included studies. Negative mean differ-
ence values indicate a treatment effect favoring surgical inter-
vention; OR results favored surgery over conventional therapy
where values and plotting points comprising the forest chart
are >1.0.
The overall (k=16; n=5,697) between-group WMD char-
acterizing BMI outcomes was −8.3 kg/m2 ([−9.6, −6.9],
p<0.001; I2=91.8 %), favoring the surgery group. The corre-
sponding pooled SMD was −1.62 ([−1.8, −1.4]; p<0.001;
I2=90.1 %); adjusted effect size, −1.95 [−2.15, −1.76].
Analysis of BMI using studies with complete data (k=6
studies, no imputation) yielded a WMD of −9.5 kg/m2
([−12.3, −6.6], p<0.001; I2=93.6 %) and corresponding
pooled SMD of −2.1([−2.7, −1.6], p<0.001; I2=85.2 %).
WMD calculations summarizing between-group compari-
sons along the HbA1C and FPG variable outcomes yielded
similar results to those found for BMI. The overall (k=12; n=
1,501) WMD for HBA1C outcomes was −1.1 % ([−1.6, −0.6],
p<0.001; I2=91.9 %), again, favoring the surgery group. The
corresponding pooled SMD was −1.0 ([−1.4, −0.6], p<0.001;
I2=89.2 %); adjusted effect size, −1.39 ([−1.72, −1.01]).
Analysis of HbA1C using studies with complete data (k=8
studies, no imputation) yielded a WMD of −1.3 % ([−1.54,
−0.98], p<0.001; I2=65.6 %) and pooled SMD of −1.13
([−1.4, −0.8], p<0.001; I2=73.2 %).
Finally, the overall (k=11; n=4,900) between-group
FPG WMD was −24.9 mg/dL ([−33.9, −15.9]; p<0.001;
I2=84.8 %), favoring the surgery group. The pooled
SMD was −0.71 ([−0.92, −0.50], p<0.001; I2=80.5 %;
adjusted effect size, −0.86 [−1.05, −0.67]). Analysis of
FPG using studies with complete data (k=5 studies, no
imputation) yielded a WMD of −36.8 mg/dL ([−56.3,
−17.3], p<0.001; I2=83.1 %) and pooled SMD of −0.96
([−1.5, −0.5], p<0.001; I2=79.9 %).
Effects of Bariatric Surgery vs Conventional Therapy
on %EWL and T2DM
Overall EWL means for the BSG and the CTG groups were
75.3 % (57.2–94.6) and 11.3 % (−5.7–29.8), respectively;
overall T2DM remission rates were 63.5 % (38.2–100.0)
and 15.6 % (0.0–46.7) (p<0.001; Table 4). Figure 5 presents
a further breakdown of %EWL and T2DM remission by
treatment group and study design. Bariatric surgery patients
enrolled in RCT designs reported the highest mean EWL
(80.0 %); bariatric surgery patients enrolled in OSs had the
highest T2DM remission rate (65.6 %).
T2DM remission event data, PORs, and 95 % CIs describ-
ing the effects of surgery vs conventional therapy on T2DM
remission are presented in the final forest plot of Fig. 4.
Independent summary estimates were calculated for RCTs
and OSs using the Peto method. The POR and 95 % CI for
combined OS remission event data (k=11; n=1,489) was 10.9
([6.1, 19.5], p<0.001; I2=81.6 %); whereas, the correspond-
ing POR and 95%CI for combined RCT remission event data
(k=5; n=404) was 7.8 ([3.3, 18.4], p<0.001; I2=70.2%), with
a high degree of 95%CI overlap. No significant heterogeneity
(Q p value=0.52) was found between the OSs’ estimate and
the RCTs’ estimate with respect to the magnitude and direc-
tion of treatment effect on T2DM remission, with the surgery
group favored in both study designs. Evaluation by z score
also indicated no statistically significant difference between
OS and RCT summary estimates (z=−0.57; p=0.57; a z score
≤−1.96 or ≥1.96 would indicate a statistically significant
difference at the 0.05 level). Thus, estimates were sufficiently
concordant to calculate an overall effect (i.e., combining
data from RCTs with OSs). As shown in Fig. 4, the (k=16;
n=1,893) summary POR was 9.8 ([6.1, 15.9], p<0.001;
I2=78.4 %).
Independent PORs and 95 % CIs were also calculated
using the inverse variance method as a direct comparison to
Peto findings. The POR and 95 % CI for combined OS data
was 18.9 ([8.1, 43.7], p<0.001; I2=79.9 %); whereas, the
corresponding POR and 95 % CI for combined RCT data
was 11.0 ([3.3, 36.3], p<0.001; I2=59.9 %), with significant
95 % CI overlap. No significant heterogeneity (Q p value=
0.47) was found between the OS and RCT summary esti-
mates, where the surgery group was favored in both study
designs. Evaluation by z score also indicated no statistically
significant difference between the independent summary esti-
mates (z=−0.60; p=0.55), the inverse variance method
yielded an overall summary POR of 15.8 ([7.9, 31.4],
p<0.001; I2=75.2 %). Thus, according to the inverse variance
method, the odds of T2DM remission in patients undergoing
bariatric surgery were, on average, 15.8 times the odds of
remission for those receiving conventional therapy. All
but one of 16 studies indicated a clear statistical advantage
favoring surgery.
Sensitivity and Subgroup Analyses
Three sensitivity analyses were performed: (1) an analysis
excluding trials reporting no remission events; (2) an analysis
excluding studies that combined data from multiple study
arms; and (3) an analysis excluding all bariatric procedures
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except RYGB (the most frequently performed procedure).
[See Electronic Supplementary Material, Appendices 2 and
3 to read the detailed results of these subgroup analyses and an
assessment of publication bias (includes Table 5 and Fig. 6).]
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Discussion
The current meta-analysis systematically identified and inte-
grated a wide range of evidence regarding the effectiveness of
bariatric surgery vs conventional therapy in promoting weight
loss and T2DM remission. Results indicated that bariatric
surgery demonstrated greater BMI reduction, greater reduc-
tion in HbA1C and FPG, and a much greater likelihood of
T2DM remission relative to patients receiving conventional
therapy.
Heterogeneity
According to the prespecified I2 value (≥75.0 %), a majority
of meta-analyses undertaken in this study were characterized
by significant heterogeneity (mean I2, 81.4 % [0–96.8]; mean
RCT, I2=72.0; mean OS, I2=86.0). Generally, when effect
estimates from individual studies rest on opposite sides of the
reference line (i.e., the point of no effect), study results are, by
definition, heterogeneous, and conclusions questionable.
However, the meta-analytic results presented in Fig. 4 showed
the vast majority of estimated effects were consistently an-
chored on the same side of the reference line, with 95 % CIs
overlapping to a great extent. Thus, when viewed in isolation,
the mean I2 statistic may be somewhat misleading.
Table 4 Excess weight loss and diabetes remission
Study %EWLa T2DM remission rate
Mean % (N)
Bariatric Conventional Bariatric Conventional p valueb
Sjöström et al. [40] 57.2 −0.3 72.0 (342) 21.0 (248) <0.001
O’Brien et al. [41] 83.9 23.5 93.0 (15) 46.7 (15) <0.01
Dixon et al. [42] 62.5 4.9 73.0 (30) 13.0 (30) <0.001
Hofsø et al. [43] 64.5 20.2 79.0 (14) 0.0 (6) <0.005
Adams et al. [44] 69.6 1.9 78.7 (61) 2.6 (114) <0.001
Serrot et al. [45] 91.7 3.3 64.7 (17) 0.0 (17) <0.001
Martins et al. [46] 69.8 23.8 67.0 (6) 36.8 (38) NS (0.17)
Iaconelli et al. [47] 62.4 29.8 100.0 (22) 45.0 (28) <0.001
Scopinaro et al. [48]c 94.6 0.0 83.0 (30) 0.0 (38) <0.001
Leonetti et al. [49] 79.8 −5.7 80.0 (30) 0.0 (30) <0.001
Mingrone et al. [50] 79.0 12.1 85.0 (40) 0.0 (20) <0.001
Heo et al. [51] 62.9 24.7 57.1 (84) 9.5 (21) <0.001
Dorman et al. [52] 85.1 −2.6 65.0 (29) 3.4 (29) <0.001
Leslie et al. [53] 67.0 −0.6 38.2 (152) 17.4 (115) <0.001
Schauer et al. [54]d 82.8 16.8 39.4 (99) 12.0 (41) <0.005
Ikramuddin et al. [55] 91.9 29.0 49.0 (57) 19.0 (57) <0.001
Overall 75.3 11.3 63.5 (1,028) 15.6 (847) <0.001
(Range) (57.2–94.6) (−5.7–29.8) (38.2–100.0) (0.0–46.7)
Negative values in the %EWL column denote mean weight gain
EWL excess weight loss, T2DM type 2 diabetes mellitus
a Standardized calculation using BMI 25 as ideal weight constant
b Z test for two population proportions
c Patients with controlled diabetes following treatment included in remission rate calculation
d Patients recovering from metabolic syndrome following treatment included in remission rate calculation
Fig. 4 The first three tables and corresponding forest plots summarize
meta-analyses of the relative effects of bariatric surgery vs conventional
therapy on body mass index (BMI), glycated hemoglobin (HbA1C), and
fasting plasma glucose (FPG). Each study contributing to a particular
meta-analysis is represented by a single darkened squarecontained on the
forest plot; the size of the square being proportional to the amount of
weight the study was given during the calculation of the pooled summary
estimate. The pooled estimate in the first three analyses is expressed as the
weighted mean difference (WMD) and is represented by the diamond
shape at the base of each forest plot. Two additional diamonds in each
forest plot represent independent summary estimates for observational
studies and randomized controlled trials. Negative WMD values indicate
a treatment effect favoring surgical intervention. The fourth table (and
forest plot) represents an analysis of the relative effects of surgery vs
conventional therapy onT2DMremission. In this case, the summary estimate
of effect is given by the pooled odds ratio (POR). Results favor surgery over
conventional therapy when odds ratio values are greater than one
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One source of heterogeneity was expected as a result of
integration of RCT and OS data. The majority of bariatric
surgery studies are observational in design, as RCTs are less
feasible to conduct for ethical and economic reasons [58].
Most RCTs are conducted in high-volume “centers of excel-
lence” according to regulated protocols that conform to na-
tional guidelines [59, 60]; therefore, RCToutcomesmay differ
significantly from OSs. Yet, interestingly, the current review’s
comparative analysis of trends in outcome variables, stratified
by study design, was highly similar (Figs. 2, 3, and 5 [see
Fig. 5 in online ESM 3]). In addition, meta-analytic results
indicated no significant heterogeneity between RCT and OS
summary estimates quantifying the relative effects of bariatric
surgery vs conventional therapy on BMI, HbA1C, and FPG
reduction. In addition, both study designs demonstrated the
superiority of bariatric surgery over conventional therapy in
promoting T2DM remission. A common criticism of OSs, in
general, is that they produce exaggerated effect sizes. While it
is true that the POR for T2DM remission derived from OS
studies was larger than that derived from RCTs (Peto, 10.9
[6.1, 19.5] vs 7.8 [3.3, 18.4]; inverse variance, 18.9 [8.1, 43.7]
vs 11.0 [3.3, 36.3]), no significant heterogeneity was found
between summary estimates. Further, Shrier et al., in their
review of the principal elements underlying this claim, found
that both study designs have strengths and weaknesses, and
including OSs would increase precision appropriately, and
may produce equally or more relevant and valid results [61].
Weight
Conventional Treatment
To place the current meta-analytic findings in context, they
should be compared to publications outside of the included
study set. The current findings in relation to BMI reduction
(WMD 1.6 kg/m2 [0.7, 2.6]) and EWL (11.3 % [−5.7–29.8])
after conventional treatment are similar to those of key
systematic reviews (SRs) and meta-analyses (MAs) [62, 63].
A SR by Tsai et al., focused on weight-loss programs across
the USA, saw 15.0–25.0 % excess body weight loss over 3–
6 months, although fewer than 9.0 % of the patients main-
tained their weight loss at 12 months [62]. In a MA by
Dansinger et al. of 46 trials that provided dietary counseling,
BMI was reduced by 1.9 units at 1 year (comparable to the 1.6
BMI units lost by the conventional therapy group in the
current meta-analysis), with a per-month BMI loss of approx-
imately 0.1 unit between 3 and 12 months of the active
counseling programs, with a BMI regain of approximately
0.02–0.03 unit per month during follow-on maintenance
phases [63].
Interestingly, while excluded from the current analysis, a
2005 comparative study, by Ritt et al., of 24 LAGB vs 16
conventional therapy patients reported an atypically large
EWL (54.5 %) [64], well outside the mean EWL (11.3 %)
for conventional therapy patients reported in our review. Also,
in a 2007 OS by Anderson et al. of 1,531 morbidly obese
conventional weight-loss patients with long-term follow-up
employing very intensive behavioral intervention (e.g.,
weight-loss camps, residential nursing programs, and closely
supervised individualized outpatient programs, possibly cost
prohibitive for many patients), marked weight loss was
achieved up to 100 lbs over the short term; however, over
1–5-year follow-up, most patients regained 34.0–41.0 %
of their lost weight [65].
Bariatric Surgery
The current findings for bariatric surgery in relation to BMI
reduction (WMD, 11.4 kg/m2 [10.0, 12.9]) and EWL (75.3 %
[57.2–94.6]) were similar to those of two SR/MAs of the
bariatric literature by Buchwald et al. [5, 22]; aggregated
weight outcomes in morbidly obese patients found 13.6 kg/m2
(12.9, 14.3) and 14.2 kg/m2 (13.2, 15.1) BMI reduction, 64.7 %
(32.0–93.0) and 55.9 % (54.1, 57.8) EWL, respectively [5, 22].
Also, an SR by Gill et al. of T2DM patients who underwent
sleeve gastrectomy (SG) with a mean 13 months of follow-up
noted 47.0 % EWL [66].
Conventional Treatment vs Bariatric Surgery
A rigorous 2009 Cochrane review by Colquitt et al. of mildly
and morbidly obese patients both with and without diabetes
found that over the short term, bariatric surgery achieved
substantially greater weight loss than medical therapy [67],
as was concluded also by Maggard-Gibbons et al., of mildly
obese diabetic patients in their 2013 SR [68]. Padwal et al.’s
2011 SR/MA of 31 RCTs, in which bariatric surgery was
compared with other bariatric surgery controls or standard
care (n=2,619; BMI 42.0–58.0) using network analysis, found
conventional treatment significantly less effective than
Fig. 5 Mean percent excess weight loss (%EWL) in bariatric surgery
patients and conventional therapy patients by study design type (random-
ized controlled trial vs observational)
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surgery over the short and intermediate terms. Padwal et al.
also found an average BMIWMD of 8.35 kg/m2 (2.4–11.4) in
their subset comparative study of all surgery vs conventional
therapy [69]. The current review’s between-group BMIWMD
was nearly identical (8.3 kg/m2 [7.0, 9.6]) to the results of
Padwal et al., which would be expected since the current
authors grouped procedures for analysis. In addition, the
pooled adjusted SMD (corresponding to the BMI WMD of
8.3 kg/m2) was 1.95 (1.76, 2.15), indicating that the average
surgery patient experienced a BMI outcome superior to that of
97.1 % of the conventional therapy group. While both treat-
ment groups in the current review can be said to have expe-
rienced a statistically significant within-group BMI change,
only the bariatric surgery patients experienced a clinically
meaningful weight reduction, as demonstrated by a mean shift
downward by as much as two obesity classifications.
Diabetes
Conventional Treatment
The long-running Look AHEAD study of weight loss by
conventional treatment (n=5,145 overweight adults with
T2DM) found an association between intensive weight-loss
intervention (ILI) and a reduction in T2DM markers: Mean
HbA1C dropped from 7.25 to 6.61 % (p<0.00). Although the
degree of success in ILI diabetes reduction experienced in the
Look AHEAD study resulted in a seemingly greater outcome
than that of the current meta-analysis, the Look AHEAD ILI
group started at a lower HbA1C than the conventional group in
the current analysis, and their overall HbA1C reduction was
proportionally similar. By this measure, Look AHEAD results
suggest that this form of therapy might be appropriate to those
patients hovering around the 7.0 % HbA1C mark at baseline.
Look AHEAD FPG outcomes for the ILI group dropped from
151.9 to 130.4 mg/dL, and were essentially identical to those
of the conventional group in the current analysis [70]; the FPG
reduction of the current analysis compared favorably, 143.1 to
123.2 mg/dL.
Bariatric Surgery
The current meta-analytic findings for overall T2DM remis-
sion (63.5 % [38.2–100.0]) and FPG reduction of 34.5 %
(down to 95.3 mg/dL) after bariatric surgery are similar to
those of a 2011 cross-sectional nRCT by Reed et al., in which
bariatric surgery patients were observed prior to and at 1 week
and 3 months following RYGB; FPG decreased to levels
similar to those (≤125/mg/dL) of lean controls (BMI ≤25),
and diabetes was considered resolved [71]. In the aforemen-
tioned SR of T2DM SG patients by Gill et al., a rate of 66.0 %
remission was recorded [66], similar to our findings for the
bariatric surgery group (63.5 %). In the 2004 SR/MA by
Buchwald et al., diabetes was completely resolved in 76.8 %
of bariatric surgery patients [5]; in the same authors’ 2009 SR/
MA that focused on T2DM outcomes in 103 treatment arms
(n=3,188), at 2-year post bariatric surgery, complete diabetes
resolution (defined therein as normal FPG and no anti-diabetic
medications) was attained by 78.1 %; at ≥2 years, 74.6 %
continued resolved [22]. AnMA of low-BMI bariatric surgery
patients by Li et al. reported a significant mean decrease in
HbA1C of 2.59 % in 80.0 % of patients after surgery,
consonant with the decrease found in our meta-analysis
(2.0 % [1.2, 2.8]) [72].
Conventional Treatment vs Bariatric Surgery
The overall T2DM remission rates for surgery patients vs
conventional therapy patients presented in the current analysis
were significantly different, 63.5 vs 15.6 % (p<0.001), re-
spectively. The relative efficacy of bariatric surgery and con-
ventional therapy in promoting T2DM remission was further
quantified in the meta-analytic calculation of PORs based on
16 studies, 94.0 % of which demonstrated a distinct statistical
advantage in favor of bariatric surgery. When the analysis was
run excluding trials reporting no remission events (which tend
to produce inflated ORs), the summary point estimates were
Peto POR of 6.9 (4.1, 11.6; inverse variance, 9.4 [5.0, 17.7],
p<0.001; I2=75.4 %), still indicative of a large effect size
favoring surgery. A second sensitivity analysis indicated that
the odds of RYGB patients reaching T2DM remission were
8.0 times those of patients treated conventionally.
Remission event data were supported by parallel clinical
evidence of T2DM remission in the form of HbA1C outcome
data. The pooled adjusted SMD quantifying the relative treat-
ment effects of surgery vs conventional therapy on HbA1C
was 1.37 (1.01, 1.72), indicating that the average surgery
patient experienced an HbA1C outcome superior to that of
90.9 % of the conventional therapy group. RCT and OS study
surgery patients experienced both statistically and clinically
significant reduction in HbA1C, moving from baseline levels
of 8.9 and 7.6 %, respectively, to 6.1 %, well below the ADA
target of ≤7.0 %. Conventional therapy patients also experi-
enced a statistically significantly reduction in HbA1C relative
to baseline; however, whether participating in an RCT or OS,
this group continued to experience poor glycemic control
(≥7.0 %) at follow-up. Glycated hemoglobin is a primary
clinical marker and predictor of T2DM. Diabetic patients have
an 11.0 % increased risk of mortality [73] from ischemic heart
disease and, those with an HbA1C >8 % are subject to a
150.0 % increased risk of death from heart disease [74].
Further, each 1.0 % increase in HbA1C has been shown to be
associated with a 20.0–30.0% increase in cardiovascular events,
and all-cause mortality independent of diabetes status [75].
The future will offer additional comparative evidence from
high-quality, experimental studies of diabetes remission
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following bariatric surgery vs conventional treatment. A mid-
2013 publication describes the start of a well-designed multi-
center RCTof lower-BMI insulin-dependent patients who will
undergo RYGB plus standard medical treatment, if needed,
compared with controls who will receive only standard T2DM
treatment; this RCT, the DiaSurg Trial, with a target size of
400 participants, will provide long-term comparative data
(8 years) on T2DM outcomes following bariatric surgery vs
conventional diabetes care [76].
Glycemic Control
Two studies in the current comparative meta-analysis provide
reason to believe that the marked improvement in glycemic
control following bariatric surgery is not only more pro-
nounced than with conventional therapy, but more durable
over the long term. Sjöström et al. reported a 96.0 % reduction
in the risk of developing T2DM and a 36.0 % rate of T2DM
remission maintenance in bariatric surgery patients at 10-year
follow-up vs an increase in T2DM incidence in the usual care
patient population [41]. Similarly, Iaconelli et al. reported
100.0 % prolongation of T2DM remission at 10-year follow-
up vs 45.0 % in the medical therapy group [48]. In addition, a
recently published follow-up report of the original, included,
O’Brien et al. study [77] shows sustained weight loss and
metabolic syndrome resolution after 10 years. All three of
these long-term findings support those of Pories et al., who
found >80.0 % improvement in T2DMmaintained at 14 years
post surgery [14], and of Li et al., whose MA of patients with
<35 BMI showed several patients in whom diabetes resolution
was maintained at 18 years following surgery [72].
Treating Lower-BMI Diabetic Patients
Multiple SR/MAs reveal a gradation in diabetes resolution
with specific bariatric operations, wherein the greatest effect is
associated with malabsorptive procedures, BPD and DS
(95.0–98.9 %) [5, 22]. Yet, 90.0 % of T2DM patients are not
morbidly obese [78–80]. The hypothesis of metabolic sur-
gery—that certain procedures, some bariatric, performed
without a primary weight-loss focus, but rather with the goal
of achieving improved control or remission of diseases such as
diabetes—has now been examined in several OSs, nRCTs,
and RCTs [15, 58, 69, 81]. In our 2010 systematic review and
integrative analysis of studies of metabolic surgery between
1979 and 2009 for treatment of T2DM in 343 patients with
BMI <35, we reported 85.3 % T2DM resolution based on an
FPG reduction of 93.3 mg/dL (105.2 mg/dL, −93.3) with
patients off antidiabetic medications, and an HbA1C reduction
of 2.7 % into the normal range (<6.0 %) in addition to
significant, not excessive, BMI loss of 5.1 (from 29.4 to
24.2) [15]. In a later review by Reis et al. that included our
SR’s original 16 papers in addition to several additional more
recently published studies, very similar results were found for
patients with BMI <35 [82].
The current meta-analytic findings relevant to treating
lower-BMI diabetic patients showed no significant heteroge-
neity between low- and high-BMI subgroups in summary
estimates quantifying the relative effects of bariatric surgery
vs conventional therapy on T2DM remission. The high-BMI
(BMI≥35) and lower-BMI (BMI<35) subgroups had respec-
tive PORs of 15.2 (6.8, 34.1) and 17.1 (4.7, 62.9). This
suggests that lower-BMI patients may also be able to experi-
ence the T2DM-reduction benefits of bariatric surgery long
observed in higher-BMI patients.
Patients whose diabetes may be treated more effectively by
bariatric surgery than conventional therapy, as found in the
current meta-analysis that sought patients with a BMI ≥25,
may benefit from the opportunity to elect T2DM treatment by
surgery. The 2009 Asian Indian Consensus Statement, for
example, recommended lowering the BMI cutoff for bariatric
surgery with a comorbidity to 32.5 [83], making surgical
treatment for diabetes available to more patients who, because
of their ethnicity, may develop severe disease at lower weights
than Caucasians [84]. Also, the 2011 International Diabetes
Federation (IDF) Task recommendation for clinical practice as
it relates to T2DM suggested that bariatric surgery should be
considered an appropriate treatment under certain circum-
stances, including failure of conventional weight and T2DM
therapy to control diabetes in those with a BMI of 30–35 [85].
Currently, however, the US National Institutes of Health
(NIH) guidelines for bariatric surgery for patients with one
or more comorbidity stipulate a BMI cutoff of ≥35, as do the
Centers for Medicare and Medicaid Services (CMS), who
maintain their 2006 policy of bariatric surgery approval only
for patients with a BMI ≥35 [59, 86].
Limitations
Only the available literature can be evaluated by a systematic
review. The analytic power of this review was limited due to
the diversity of T2DM diagnosis and remission standards
reported. Most studies determined T2DM outcomes idiosyn-
cratically; the majority of studies did not define T2DM remis-
sion uniformly, some employing ADA or NIH measures, and
others, only biochemical marker of glycemic control. Al-
though the number of available RCTs was noteworthy,
representing almost one third of included studies, there is a
shortage of well-controlled observational and level 1
(experimental) evidence comparing bariatric surgery and con-
ventional therapy outcomes; a greater number of well-
designed experimental studies would have increased this re-
view’s predictive strength. A uniform standard for reporting
T2DM remission is needed to improve the scientific evidence
base and support clinical decision making. Another limitation
of the analysis was that three studies, included because they
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met all comparative study requirements, incorporated conven-
tional therapy arms that included no patient treatment, and
simply followed patients who received no focused weight-loss
intervention as a measure of “conventional treatment”.
Another possible limitation of this study was the use of
standard deviation imputation in order to allow for inclusion
of reported mean data that were not accompanied by variance
data. In an effort to assess imputation bias, parallel analyses of
between-group outcomes were carried out, incorporating into
the meta-analyses only those studies with complete data, as
originally abstracted. Without exception, imputation was
shown to slightly constrain effect size. Also, the grouping of
bariatric procedures may have introduced bias; however, sen-
sitivity analysis demonstrated that the grouping technique, as
applied in this research, also served to constrain effect size.
Thus, SMDs reported herein likely represent relatively con-
servative summary estimates. Finally, our analyses afforded
mainly short-term results: Comparative data for weight and
T2DM remission in bariatric surgery vs conventional therapy
at follow-up time points greater than 17.3 months are needed.
Conclusions
The current research summarizes the best available findings
for weight loss and T2DM remission in directly comparative
research studies of surgery vsmedical therapy inmildly obese,
obese, and morbidly obese patients, a treatment effect corrob-
orated by the analysis of HbA1C reduction. The current review
demonstrates that surgery has a dramatically greater weight-
loss effect, by ≥3 orders of magnitude, and a more expeditious
and higher rate of T2DM remission than conventional therapy.
Physicians must appraise the evidence for bariatric surgery
vs conventional therapy on a patient-by-patient basis,
weighing complications and costs associated with surgery
against those associated with uncontrolled T2DM and/or co-
morbid obesity. However, only 1.0–3.0 % of individuals who
reach class I obesity ever return to normal weight through
conventional means [87], and a significant proportion of them
go on to develop T2DM. Thus, the current meta-analytic
finding, that the effectiveness of treatment with bariatric sur-
gery far exceeds that of conventional therapy, carries the
additional implication that surgery should be considered as a
preventive measure.
In this systematic review and meta-analysis of 16 compar-
ative studies of 6,131 patients with a baseline BMI ranging
from 30.2 to 51.5 at mean 17-month follow-up, bariatric
surgery was significantly more effective in achieving weight
loss, HbA1C reduction, and diabetes remission than conven-
tional medical therapy. Based on overall summary estimates,
the odds of T2DM remission in patients undergoing bariatric
surgery were calculated to be from 9.8 to 15.8 times the odds
of remission for those patients receiving conventional therapy,
a finding that held true regardless of study design, severity of
T2DM (as measured by baseline HbA1C), preoperative BMI,
age, or weight loss.
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